Yizun Biomedicine’s CNK-UT Cell Therapy Initiates Patient Enrollment for Solid Tumor Trial
Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...
HKG: 1513
Livzon Pharmaceutical Secures Exclusive Rights to Onconic’s GERD Treatment Zastaprazan
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with South Korean...
Livzon Launches National Rollout of COVID-19 Vaccine V-01 in China
China-based Livzon Pharmaceutical Group (HKG: 1513) has announced the national promotion of its recombinant novel...
CanSino, Livzon Win China EUAs for COVID-19 Booster Vaccines
China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have...
Livzon’s V-01 and V-01D-351 Vaccines Show Strong Safety, Immunity as COVID Boosters
China-based Livzon Pharmaceutical Group (HKG: 1513) released clinical data for its recombinant novel coronavirus fusion...